ClinicalTrials.Veeva

Menu

A Phased-Implementation Feasibility and Proof-of-Concept Study to Assess Incorporating the NIDA CTN Common Data Elements (CDEs) Into the Electronic Health Record (EHR) in Large Primary Care Settings ("CDE-EHR-PC" Study), Phase 3

NYU Langone Health logo

NYU Langone Health

Status

Completed

Conditions

Substance Abuse

Treatments

Behavioral: Patient surveys
Behavioral: the SAAS survey
Behavioral: Meetings with implementation leader(s)

Study type

Observational

Funder types

Other
NIH

Identifiers

NCT02963948
CTN-0062Ot (Other Identifier)
16-01373

Details and patient eligibility

About

This is a 4-phase study to implement the NIDA CDEs in primary care settings. Collecting and utilizing the CDEs in clinical practice requires a strategy for implementing screening to collect substance use information that populates the CDEs, and assisting primary care medical staff to offer appropriate interventions by providing clinical decision support (CDS) and a mechanism for making referrals to addiction treatment. Investigators aim to maximize the efficient adoption of screening, CDS, and treatment referrals by integrating all of these activities into the electronic health record (EHR).

The study will be conducted at three sites, representing three large health systems. Each phase will include deliverables essential to move to the next phase, and an independent Advisory Committee will review progress and make recommendations at each transition about how best to progress to each subsequent phase. Based on progress during earlier phases, the Advisory Committee may recommend expansion to additional clinics or health systems during the second part of Phase 4.

Full description

SPECIFIC AIMS

  1. To program the NIDA CTN CDEs, the NIDA/ASAM electronic Clinical Quality Measure (eCQM), and a lean decision support module into Epic.

  2. To study the process of implementation of screening and referral using Epic-driven CDEs and CDS in three primary care clinics / practices, including defining potential barriers and facilitators to their adoption.

  3. To evaluate the impact of implementation on:

    • Patient level outcomes (diagnosis, treatment referral);
    • Medical staff level outcomes (screening and assessment, clinical interventions including counseling and treatment referral); and
    • Systems level outcomes (logistics and costs of introducing the CDEs, feasibility).

Enrollment

113,123 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • English speaking adult individuals age 18 years or older, and current employee or patient at a Wave 1 clinic with direct patient contact.

Exclusion criteria

  • Inability to provide informed consent.

Trial design

113,123 participants in 6 patient groups

Clinic A1
Treatment:
Behavioral: the SAAS survey
Behavioral: Patient surveys
Behavioral: Meetings with implementation leader(s)
Clinic A2
Treatment:
Behavioral: the SAAS survey
Behavioral: Patient surveys
Behavioral: Meetings with implementation leader(s)
Clinic B1
Treatment:
Behavioral: the SAAS survey
Behavioral: Patient surveys
Behavioral: Meetings with implementation leader(s)
Clinic B2
Treatment:
Behavioral: the SAAS survey
Behavioral: Patient surveys
Behavioral: Meetings with implementation leader(s)
Clinic B3
Treatment:
Behavioral: the SAAS survey
Behavioral: Patient surveys
Behavioral: Meetings with implementation leader(s)
Clinic B4
Treatment:
Behavioral: the SAAS survey
Behavioral: Patient surveys
Behavioral: Meetings with implementation leader(s)

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems